You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

10 Results
Guidelines and Advice
Status: In-Review
ID: 17-4
Version: 2
Nov 2016
Statistical Reports
Jun 2016
Cancer facts
Sep 2016
Drug
Other Name(s): Sandostatin® (multiple brands available) , Sandostatin® LAR™ (Novartis)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2016
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
vinCRIStine,
procarbazine,
prednisone,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2019
Guidelines and Advice
Status: Current
ID: GL 5-3ORG
Version: 2
Apr 2019
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: N/A
Oct 2019